Last reviewed · How we verify
IgG Next Generation (BT595)
IgG Next Generation (BT595) is a Intravenous immunoglobulin (IVIG) Biologic drug developed by Biotest. It is currently in Phase 3 development for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (specific indications in Phase 3 trials not publicly detailed). Also known as: Immune Globulin Intravenous (Human), 10% Liquid.
BT595 is a next-generation intravenous immunoglobulin (IVIG) product designed to provide passive immunity through polyclonal IgG antibodies with enhanced manufacturing and purification processes.
IgG Next Generation (BT595) is a small molecule being studied for its efficacy, safety, and pharmacokinetics in subjects with Primary Immunodeficiency Disease. It is being investigated in an open-label, prospective, multicenter study.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IgG Next Generation (BT595) |
|---|---|
| Also known as | Immune Globulin Intravenous (Human), 10% Liquid |
| Sponsor | Biotest |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a next-generation IVIG, BT595 contains pooled immunoglobulin G from multiple human donors to provide broad-spectrum passive immunity. The 'next generation' designation suggests improvements in manufacturing, viral safety, stability, or reduced adverse event profiles compared to standard IVIG formulations. It functions by supplying exogenous antibodies to patients with immunodeficiency or autoimmune/inflammatory conditions.
Approved indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency
- Autoimmune and inflammatory conditions (specific indications in Phase 3 trials not publicly detailed)
Common side effects
- Infusion reactions (headache, fever, chills)
- Thromboembolism
- Aseptic meningitis
- Hemolytic anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgG Next Generation (BT595) CI brief — competitive landscape report
- IgG Next Generation (BT595) updates RSS · CI watch RSS
- Biotest portfolio CI
Frequently asked questions about IgG Next Generation (BT595)
What is IgG Next Generation (BT595)?
How does IgG Next Generation (BT595) work?
What is IgG Next Generation (BT595) used for?
Who makes IgG Next Generation (BT595)?
Is IgG Next Generation (BT595) also known as anything else?
What drug class is IgG Next Generation (BT595) in?
What development phase is IgG Next Generation (BT595) in?
What are the side effects of IgG Next Generation (BT595)?
Related
- Drug class: All Intravenous immunoglobulin (IVIG) drugs
- Manufacturer: Biotest — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Primary immunodeficiency disorders
- Indication: Drugs for Secondary immunodeficiency
- Indication: Drugs for Autoimmune and inflammatory conditions (specific indications in Phase 3 trials not publicly detailed)
- Also known as: Immune Globulin Intravenous (Human), 10% Liquid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing